Vladimír Uličiansky
Program DIASAVE PLUS involved 1 419 patients who were treated in 112 diabetological out-patient clinics in Slovakia. The aim of the program was to collect pharmacoepidemiological data about occurrence of risk factors and complications in patients with type 2 diabetes. At the same time the effect of therapy with gliklazid MR to cardiovascular risk factors was monitored. Results of the program show that patients with type 2 diabetes represent a high risk group. Addition of gliklazid MR to the therapy in various subgroups of patients led to decreasing levels of HbA1c, of fasting glycemia, postprandial glycemia, decrease of 10-year risk of ichaemic heart disease (IHD) and 10-year risk of fatal IHD. Gradual titration of a dose of gliklazid MR results in target values of HbA1c < 6.5 % and thus contributes to decrease of an important risk factor of microvascular and macrovascular complications of diabetes.